Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breas... von Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., Yap, Y.S., Sonke, G.S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K.L., Winer, E.P., Janni, W., Verma, S., Conte, P., Arteaga, C.L., Cameron, D.A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., Germa, C., O’Shaughnessy, J.

Volltext

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breas... von Hortobagyi, G.N., Stemmer, S.M., Burris, H.A., Yap, Y.S., Sonke, G.S., Paluch-Shimon, S., Campone, M., Petrakova, K., Blackwell, K.L., Winer, E.P., Janni, W., Verma, S., Conte, P., Arteaga, C.L., Cameron, D.A., Mondal, S., Su, F., Miller, M., Elmeliegy, M., Germa, C., O’Shaughnessy, J.

Volltext

Efficient Preconditioned Soil–Foundation–Structure Interaction Approach to Compute Tall-Building Time Periods von Elmeliegy, A. M, Rashed, Youssef F

Volltext

Correlation-based full-waveform shear wave elastography von Elmeliegy, Abdelrahman M, Guddati, Murthy N

Volltext

Full waveform inversion through double-sweeping solver von Eslaminia, Mehran, Elmeliegy, Abdelrahman M., Guddati, Murthy N.

Volltext

Exposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial von Yu, Y., Elmeliegy, M., Litton, J.K., Tudor, I.C., Czibere, A., Zheng, J., Wang, D.D.

Volltext

Exposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials von Elmeliegy, M., Yu, Y., Litton, J.K., Turner, N.C., Czibere, A., Wilson, G.G., Tudor, I.C., Zheng, J., Wang, D.D.

Volltext

The Link Between Pharmacodynamics and Physiologically Based Pharmacokinetic Models von Perera, V, Elmeliegy, M A, Rao, G, Forrest, A

Volltext

307 Population pharmacokinetic and pharmacodynamic modeling of bevacizumab and a proposed biosimilar (GP2019) in healthy male volunteers von Elmeliegy, M, Potocka, E, Renard, D, Kakar, S, Skerjanec, A, Li, Y, Castro, H, Izquierdo, M, Barker, D

Volltext

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN–DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISM... von Nooka, A, Lesokhin, A, Mohty, M, Niesvizky, R, Maisel, C, Arnulf, B, Larson, S, Varshavsky-Yanovsky, A, Leleu, X, Karlin, L, Vesole, D, Bahlis, N, Larrea, CF, Raje, N, Leip, E, Conte, U, Elmeliegy, M, Viqueira, A, Blunk, V, Manier, S

Volltext

PB2032: MAGNETISMM‐9: AN OPEN‐LABEL, MULTICENTER, NON‐RANDOMIZED PHASE 1/2 STUDY OF ELRANATAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA von Fonseca, R., Kuroda, J., Ishida, T., Popat, R., Huang, J. S., Yver, A., Vandendries, E., Elmeliegy, M., Ma, W. D., Sborov, D. W.

Volltext

Full-waveform shear wave elastography for imaging tumors von Elmeliegy, Abdelrahman M., Guddati, Murthy

Volltext

Shear wave elastography: From dispersion matching to full waveform inversion von Guddati, Murthy, Roy, Tuhin, Elmeliegy, Abdelrahman M., Urban, Matthew W.

Volltext

305PExposure-efficacy progression-free survival (PFS) analyses of breast cancer patients with germline BRCA1/2 mutations receiving talazoparib in the phase III EMBRACA trial von Yu, Y, Elmeliegy, M, Litton, J K, Tudor, I C, Czibere, A, Zheng, J, Wang, D D

Volltext

306PExposure-safety analyses in breast cancer patients with germline BRCA1/2 mutations receiving talazoparib (TALA) in EMBRACA and ABRAZO trials von Elmeliegy, M, Yu, Y, Litton, J K, Turner, N C, Czibere, A, Wilson, G G, Tudor, I C, Zheng, J, Wang, D D

Volltext

Assessment of gastric pH changes and food intake on ribociclib bioavailability: In silico and clinical evaluations von Samant, T., Elmeliegy, M., Dhuria, S., Lu, Y., Laisney, M., Yang, S., Grandeury, A., Mueller-Zsigmondy, M., Umehara, K-I., Huth, F., Miller, M., Germa, C.

Volltext

Abstract P1-14-05: Ribociclib dose recommendations for potential pharmacokinetic drug interaction and in special patient populations with organ impairment von Abdelhady, AM, Samant, TS, Chakraborty, A, Germa, C, Liu, X, Umehara, K-I, Huth, F, Lu, Y, Yang, S, Quinlan, M, Laisney, M, Mueller-Zsigmondy, M, Elmeliegy, M

Volltext

Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breas... von Hortobagyi, G N, Stemmer, S M, Burris, H A, Yap, Y S, Sonke, G S, Paluch-Shimon, S, Campone, M, Petrakova, K, Blackwell, K L, Winer, E P, Janni, W, Verma, S, Conte, P, Arteaga, C L, Cameron, D A, Mondal, S, Su, F, Miller, M, Elmeliegy, M, Germa, C, O'Shaughnessy, J

Volltext

Role of ATP-Binding Cassette and Solute Carrier Transporters in Erlotinib CNS Penetration and Intracellular Accumulation von ELMELIEGY, Mohamed A, CARCABOSO, Angel M, TAGEN, Michael, FENG BAI, STEWART, Clinton F

Volltext

Tyrosine Kinase Inhibitor Gefitinib Enhances Topotecan Penetration of Gliomas von CARCABOSO, Angel M, ELMELIEGY, Mohamed A, JUN SHEN, JUEL, Stephen J, ZHANG, Ziwei M, CALABRESE, Christopher, TRACEY, Lorraine, WATERS, Christopher M, STEWART, Clinton F

Volltext